BofA raised the firm’s price target on Amylyx (AMLX) to $16 from $14 and keeps a Buy rating on the shares after including net proceeds from the follow-on after the company raised $175M, for net proceeds of $163M, by issuing 17.5M shares at a price of $10 each. The balance sheet boost gives the company flexibility to invest in commercial ramp-up activities at or near the time of Phase 3 LUCIDITY trial results readout for avexitide for post-bariatric hypoglycemia, the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMLX:
- Strategic Growth and Financial Flexibility Position Amylyx Pharmaceuticals for Success: Buy Rating with $16 Price Target
- Amylyx price target raised to $25 from $17 at Guggenheim
- Amylyx Pharmaceuticals Announces $164 Million Stock Offering
- Amylyx 17.5M share Spot Secondary priced at $10.00
- Amylyx announces common stock offering, no amount given